Companies › Kyntra Bio
1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FG-3246 anti-CD46 antibody-drug conjugate | CD46 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Mar 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06842498 | FG-3246 | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | Oncology | Mar 2028 |
Cash and short-term investments of $91m on 2026-06-30; operating cash outflow about $36m a year; runway about 30 months at that burn, to Jan 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Black Diamond Therapeutics CNS Pharmaceuticals Faeth Therapeutics BioLineRx Allarity Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.